Education
About Us
Working with TipRanks
Follow Us
Chordia Therapeutics Inc. (JP:190A)
:190A
Total Valuation
Chordia Therapeutics Inc. has a market cap or net worth of ¥7.09B. The enterprise value is ¥9.87B.
Market Cap¥7.09B
Enterprise Value¥9.87B
Share Statistics
Chordia Therapeutics Inc. has 70,180,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,180,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Chordia Therapeutics Inc.’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -73.54%.
Return on Equity (ROE)-0.73
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-73.54%
Return on Capital Employed (ROCE)-0.73
Revenue Per Employee0.00
Profits Per Employee-81.07M
Employee Count22
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Chordia Therapeutics Inc. is ―. Chordia Therapeutics Inc.’s PEG ratio is 0.42.
PE Ratio―
PS Ratio0.00
PB Ratio5.07
Price to Fair Value5.07
Price to FCF-6.70
Price to Operating Cash Flow0.00
PEG Ratio0.42
Income Statement
In the last 12 months, Chordia Therapeutics Inc. had revenue of 0.00 and earned -1.79B in profits. Earnings per share was -26.03.
Revenue0.00
Gross Profit-1.43B
Operating Income-1.79B
Pretax Income-1.78B
Net Income-1.79B
EBITDA-1.79B
Earnings Per Share (EPS)-26.03
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Chordia Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.23
52-Week Price Change-57.09%
50-Day Moving Average112.12
200-Day Moving Average189.09
Relative Strength Index (RSI)44.69
Average Volume (3m)565.44K
Important Dates
Chordia Therapeutics Inc. upcoming earnings date is Jan 20, 2026, TBA (Confirmed).
Last Earnings DateOct 10, 2025
Next Earnings DateJan 20, 2026
Ex-Dividend Date―
Financial Position
Chordia Therapeutics Inc. as a current ratio of 10.92, with Debt / Equity ratio of 0.00%
Current Ratio10.92
Quick Ratio10.92
Debt to Market Cap0.00
Net Debt to EBITDA1.43
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Chordia Therapeutics Inc. has paid 2.42M in taxes.
Income Tax2.42M
Effective Tax Rate>-0.01
Enterprise Valuation
Chordia Therapeutics Inc. EV to EBITDA ratio is -5.48, with an EV/FCF ratio of -5.32.
EV to Sales0.00
EV to EBITDA-5.48
EV to Free Cash Flow-5.32
EV to Operating Cash Flow-5.34
Balance Sheet
Chordia Therapeutics Inc. has ¥2.82B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of ¥2.82B billion.
Cash & Marketable Securities¥2.82B
Total Debt¥0.00
Net Cash¥2.82B
Net Cash Per Share¥40.21
Tangible Book Value Per Share¥35.52
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Chordia Therapeutics Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―